Immunome Inc Stock Price, News & Analysis

Immunome, Inc. (Nasdaq: IMNM) presented findings on its anti-interleukin-38 monoclonal antibody program at the 2021 AACR-NCI-EORTC International Conference. The presentation revealed that the antibody effectively binds to IL-38, preventing its interaction with receptors and enhancing myeloid cell activity in vitro. In murine tumor models, the antibody significantly inhibited tumor growth. This data suggests that blocking IL-38 could potentially reverse immune suppression in tumors, providing a promising avenue for cancer treatment.

Immunome, Inc. (NASDAQ: IMNM) announced an oral poster presentation of its anti IL-38 antibody program at the 2021 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, scheduled for October 7-10, 2021. The presentation, titled “IMM20324, a first-in-class, anti-interleukin-38 monoclonal antibody,” will cover the antibody's effectiveness in inducing robust anti-tumor responses in vivo. This marks a significant milestone for Immunome as it advances its therapeutic programs targeting oncology and infectious diseases, including COVID-19.

Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company focused on antibody therapeutics, announced that President and CEO Purnanand Sarma, Ph.D., will present at the Cantor Global Healthcare Conference on September 29, 2021, at 8:40 a.m. ET. Interested parties can access the live audio webcast through the company's Investor Relations page. Immunome leverages its human memory B cell platform to develop first-in-class therapeutics targeting oncology and infectious diseases, including COVID-19.

Immunome, Inc. (Nasdaq: IMNM) announced that its President and CEO, Purnanand Sarma, will present at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit on September 21, 2021, at 9:55 a.m. ET. The live audio webcast can be accessed from the Investor Relations section of the company's website and will be available for replay for 30 days following the event. Immunome is focused on developing first-in-class antibody therapeutics, targeting oncology and infectious diseases, including COVID-19.

Immunome, Inc. (Nasdaq: IMNM) announced that its antibody cocktail, IMM-BCP-01, showed strong neutralizing activity against the Lambda and Delta variants of SARS-CoV-2 in pre-clinical studies. The cocktail targets non-overlapping regions of the spike protein, proving effective against multiple strains. Funded by the U.S. Department of Defense, this promising therapeutic aims to combat COVID-19 variants. CEO Purnanand Sarma emphasized the ongoing support from pre-clinical data, reinforcing the importance of IMM-BCP-01 in fighting emerging variants.

Immunome, Inc. (Nasdaq: IMNM) reported robust progress in Q2 2021, particularly in developing IMM-BCP-01, an antibody cocktail targeting SARS-CoV-2. The company secured increased funding from the Department of Defense and demonstrated strong neutralization activity against the Delta variant in preclinical tests. An IND filing for IMM-BCP-01 is planned for Q3 2021, with additional plans for an IL-38 immuno-oncology IND filing in Q4 2021. Financially, R&D expenses were $3.2 million, and the net loss totaled $5.2 million, with cash reserves at $59.8 million.

Immunome (Nasdaq: IMNM) announced promising results for its three-antibody cocktail, IMM-BCP-01, which showed potent neutralizing activity against the SARS-CoV-2 Delta variant in pre-clinical tests. The company received a $17.6 million award from the U.S. Department of Defense to support its COVID program. With concerns over potential COVID-19 resurging due to new variants, Immunome plans to expedite the development of IMM-BCP-01 and submit an IND application to the FDA this quarter, potentially positioning the drug as a long-term solution to COVID-19.

Immunome, a biopharmaceutical company focused on first-in-class antibody therapeutics, announced that its President and CEO, Purnanand Sarma, Ph.D., will present at the Ladenburg Thalmann 2021 Healthcare Conference on July 13, 2021, at 10:30 a.m. ET. The presentation can be accessed via a live audio webcast on the company’s website, with a replay available for 30 days. Immunome leverages its human memory B cell discovery engine to develop therapies for oncology and infectious diseases, including COVID-19.

Immunome, Inc. (Nasdaq: IMNM) has appointed Andrew D. Badley, M.D., to its COVID-19 Advisory Board. Dr. Badley, Chair of the Mayo COVID-19 Research Taskforce, is recognized for his expertise in infectious diseases and will provide critical insights as Immunome develops antibody therapeutics for COVID-19 and other outbreaks. His extensive background includes significant roles at the Mayo Clinic and a focus on virus-host interactions, aiming to enhance therapeutic approaches in infectious diseases.